系统性红斑狼疮的卫生经济学评价研究进展OA

Systemic lupus erythematosus(SLE)is a chronic autoimmune disease characterized by mul-tisystem involvement and long-term disease burden.In China,both the incidence and prevalence of SLE exceed global averages,with over one million patients affected.As an essential instrument for quantifying disease-relat-ed economic burden,health economic evaluation plays a key role in informing evidence-based decision-making for treatment strategies and healthcare policies.Beginning with an overview of cost-of-illness(COI)analyses in SLE,this review further examines the scope,strengths,limitations,and real-world applications of four major methodologies:cost-effectiveness analysis(CEA),cost-utility analysis(CUA),cost-benefit analysis(CBA),and cost-minimization analysis(CMA).As a result,SLE generates substantial direct,indirect,and intangible costs.While COI studies often emphasize direct medical expenses,productivity loss and deterio-ration in quality of life constitute a significant portion of the overall economic burden and deserve comparable consideration.CEA and CUA are widely employed,particularly for biologics such as belimumab,and frequent-ly demonstrate favorable cost-effectiveness under accepted willingness-to-pay thresholds.In contrast,CBA and CMA remain infrequently used due to methodological challenges.Future research should prioritize the develop-ment of culturally appropriate utility value sets in China and the integrated application of diverse evaluation ap-proaches in local healthcare settings.